HighTower Advisors
AKBA icon

HighTower Advisors’s Akebia Therapeutics AKBA Stock Holding History

HighTower Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,000
Closed -$2K – 2592
2020
Q3 		$2K Buy
+3,000
New +$26.3K ﹤0.01% 2500

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HighTower Advisors's AKBA Position: Q2 2026 in Review

HighTower Advisors increased its Akebia Therapeutics (AKBA) stake by 24% in Q2 2026, buying an estimated $8.84K and bringing the position to 38,568 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #3737.

HighTower Advisors first reported a position in AKBA in Q2 2019 and has held it in 29 quarters since. The position peaked at $493K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • HighTower Advisors held 38,568 shares of Akebia Therapeutics worth $44K as of Q2 2026.
  • HighTower Advisors bought 7,424 Akebia Therapeutics shares in Q2 2026, an estimated $8.84K.
  • Akebia Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3737 holding.
  • HighTower Advisors first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • HighTower Advisors's Akebia Therapeutics position peaked at $493K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.